January 1, 2017Journal of Zhejiang University SCIENCE B

Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice

View Full Paper

Ask AI

Bookmark

Why the study?

Does liposomal doxorubicin improve therapeutic efficacy and reduce side effects in patients with breast cancer receiving adjuvant chemotherapy?

Population

Patients with breast cancer receiving adjuvant chemotherapy

Design

Review

Authors

MZMing ZhaoNanjing University of Chinese Medicine XDXianfeng DingZhejiang Sci-Tech University XDXian-feng DingZhejiang Sci-Tech University

Discussion

Member takes

Implication

Liposomal carriers may enhance adjuvant chemotherapy tolerability in breast cancer; leaves open efficacy confirmation in randomized trials.

Structured PICO

Does liposomal doxorubicin improve therapeutic efficacy and reduce side effects in patients with breast cancer receiving adjuvant chemotherapy?

Population

Patients with breast cancer receiving adjuvant chemotherapy

Intervention

Liposomal doxorubicin (pegylated liposomal doxorubicin [PLD] and non-PLD [NPLD])

Outcome

Therapeutic efficacy and side effects

This review summarizes the therapeutic efficacy and side effects of liposomal doxorubicin in breast cancer adjuvant chemotherapy to guide clinical practice and future research.

Cite This Study

Zhao et al. (2017) studied this question.

synapsesocial.com/papers/6a73962bd3d4e530dbfb6f41 https://doi.org/10.1631/jzus.b1600303

View Full Paper

Ask AI

Bookmark

Implication

Liposomal carriers may enhance adjuvant chemotherapy tolerability in breast cancer; leaves open efficacy confirmation in randomized trials.